Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in Rare Tumors
NCT02721732Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2016
- Primary completion
- Dec 2028
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in rare tumors and solid tumor, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Non-progression Rate at 27 weeks. Started Aug 2016; status: active, not recruiting.
02
Drugs
03
Conditions
rare tumorssolid tumor
Beyond the preview
Go deeper on NCT02721732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02721732.